Committee on Veterans' Affairs. Hearings held.

Original title: “S 1014: A bill to amend title 38, United States Code, to require the Secretary of Veterans Affairs in the management of health care services for veterans to place certain low-income veterans in a higher health-care priority category.”

Placed on Senate Legislative Calendar under General Orders. Calendar No. 190.

Original title: “S 1188: Department of Veterans Affairs Medical Programs Enhancement Act of 2001”

Committee on Veterans' Affairs. Hearings held. Hearings printed: S.Hrg. 108-874.

Original title: “S 50: Veterans Health Care Funding Guarantee Act of 2003”

Committee on Veterans' Affairs. Hearings held. Hearings printed: S.Hrg. 107-635.

Original title: “SRES 61: A resolution expressing the sense of the Senate that the Secretary of Veterans Affairs should recognize board certifications from the American Association of Physician Specialists, Inc., for purposes of the payment of special pay by the Veterans Health Administration.”

We are at a critical inflection point in therapy development, with the opportunity to build on scientific momentum to unlock complex rare diseases and save lives. Our rare disease community is eager to support FDA leaders […] The post EveryLife Foundation Highlights Rare Disease Regulatory Recommendations and the Community’s Eagerness to Work with FDA’s New Leadership appeared first on EveryLife Foundation for Rare Diseases.

Original title: “EveryLife Foundation Highlights Rare Disease Regulatory Recommendations and the Community’s Eagerness to Work with FDA’s New Leadership”

The Food and Drug Administration (FDA) is classifying the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms. We are taking this action because we have determined that classifying the device into class II will provide a r

Original title: “Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms”

The Office of Management and Budget (OMB) proposes to revise the Guidance for Federal Financial Assistance to improve government- wide policies and requirements related to the management of grants, cooperative agreements, and other forms of assistance. OMB is proposing revisions that would improve transparency, accountability, and oversight for Federal awards across the Federal Government. This includes ensuring that American tax dollars are not wasted or misused, activities performed under Fede

Original title: “Regulation for Federal Financial Assistance”

The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Patient-Focused Drug Development for Nonhealing Chronic Wounds." The purpose of the public meeting is to obtain patient perspectives about the impact of nonhealing chronic wounds on daily life, patient views on treatment approaches, factors to consider when selecting a treatment, and what they consider when determining whether to participate in a clinical trial.

Original title: “Patient-Focused Drug Development for Nonhealing Chronic Wounds; Public Meeting; Request for Comments”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Statistical Approaches to Establishing Bioequivalence." This guidance provides recommendations to sponsors and applicants planning to use equivalence criteria in analyzing bioequivalence (BE) studies for investigational new drug applications (INDs), new drug applications (NDAs), abbreviated new drug applications (ANDAs), and amendments and supplements to these applications.

Original title: “Statistical Approaches To Establishing Bioequivalence; Guidance for Industry; Availability”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA." This guidance provides recommendations to applicants planning to include bioequivalence (BE) information in abbreviated new drug applications (ANDAs), ANDA amendments, and ANDA supplements. In addition, this guidance describes how to meet the BE requirements set forth in the Federal Foo

Original title: “Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Guidance for Industry; Availability”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Content of Human Factors Information in Medical Device Marketing Submissions." This guidance provides a risk-based framework to guide manufacturers and FDA staff on the human factors information that should be included in a marketing submission to the Center for Devices and Radiological Health (CDRH) to facilitate the efficiency of the FDA review process.

Original title: “Content of Human Factors Information in Medical Device Marketing Submissions; Guidance for Industry and Food and Drug Administration Staff; Availability”

The Food and Drug Administration (FDA) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Psychopharmacologic Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2028, expiration date.

Original title: “Advisory Committee; Psychopharmacologic Drugs Advisory Committee; Renewal”

The Centers for Disease Control and Prevention (CDC), a component of the Department of Health and Human Services (HHS), announces the issuance of an Amended Order under Section 362 and 365 of the Public Health Service Act that suspends the introduction of certain persons from countries where an outbreak of a communicable disease exists for a period of 30 days. The Amended Order was issued on May 22, 2026.

Original title: “Notice of an Amended Order Under Sections 362 and 365 of the Public Health Service Act Suspending Introduction of Certain Persons From Countries Where a Communicable Disease Exists”

Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S2841-2842)

Original title: “SRES 208: A resolution supporting the designation of May 10, 2025, as "National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day".”

Referred to the House Committee on Energy and Commerce.

Original title: “HRES 1260: Supporting the designation of May 10, 2026, as "National Asian American, Native Hawaiian, and Pacific Islander Mental Health Day".”

Committee on Energy and Natural Resources Subcommittee on Public Lands, Forests, and Mining. Hearings held. With printed Hearing: S.Hrg. 117-301.

Original title: “S 1264: Resiliency for Ranching and Natural Conservation Health Act”

UK market access needs the right conditions nationally, along with subnational investment and delivery locally Subnational access is 40% of the access strategy Often market access success is measured by a positive HTA; in the UK, a positive NICE TA. Over time, pharma companies have become attuned to going further with market access, into the complexity of healthcare systems to ensure patients can actually gain access to innovative medicines at the point of prescribing. NICE analysis suggests a further three to five new medicines per year will receive a positive technology appraisal following the changes. This is three to five additional new medicines available for UK patients in areas of high unmet need and in step-change therapies. Market access can be viewed through different lenses depending on if you are in health economics, pricing and reimbursement or subnational access. Regardless of your lens, in market access you are in the business of ensuring that innovative medicines reach patients and that market access barriers to prescribing are removed. This is what subnational access deals with, and what de-risking the market access strategy requires. We need the right conditions nationally. We also need investment and delivery locally. When these are combined, the root causes and barriers to medicines adoption will be removed. Patient outcomes then will be achieved.

Original title: “Closing the last mile: translating national market access into real-world patient access in the UK - PMLiVE”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 1232: Workplace Violence Prevention for Health Care and Social Service Workers Act”

Referred to the Committee on Education and Workforce, and in addition to the Committees on Energy and Commerce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 2531: Workplace Violence Prevention for Health Care and Social Service Workers Act”

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 3415: Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act of 2025”